Q4 EPS Estimate for United Therapeutics Lowered by Analyst
Equities research analysts at Leerink Partnrs dropped their Q4 2024 earnings per share estimates for United Therapeutics in a ...
Research Analysts Issue Forecasts for UTHR FY2024 Earnings
Leerink Partnrs dropped their FY2024 earnings per share estimates for shares of United Therapeutics in a research report ...
Relay Therapeutics: A Precision Oncology Play Worth The Risk
Relay Therapeutics' financial stability is strong, but zero Q3 2024 revenue and rising net losses raise concerns. Find out ...
Royalty Pharma's Strong Portfolio Growth and Manager Acquisition Boost Long-Term Outlook
In this process, royalty recipients often face the issue where multiple small future royalty streams cannot fulfill ongoing large lump-sum R&D funding needs. The mismatch is where Royalty Pharma ...